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We report about an infant aﬀected by dilated cardiomyopathy (CMP) in whom metabolic investigations evidenced medium-
chain-acyl-CoA dehydrogenase deﬁciency (MCADD), that is one of three types of inherited disorders of mitochondrial fatty-acid
β-oxidation. Long-chain and very long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deﬁcits are recognized as responsible of
hypertrophic or, less frequently, dilated cardiomyopathy (CMP) in childhood. Otherwise, to our knowledge, no case of MCADD
associated to dilated CMP has been reported in literature.
Copyright © 2009 M. Marc` ı and P. Ajovalasit. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.CaseReport
A 2-month-old female infant with severe dilated CMP, put
on medication with digitalis and diuretics, was referred to
our Institution to undergo heart transplant. Her twin sister
died suddenly in the ﬁrst few days of life, and a clear cause
of death was not demonstrated. Initial physical examina-
tion revealed growth retardation, due to failure to thrive,
hypotonia, S3 gallop, tachypnea, and liver enlargement. The
echocardiogram showed severe left ventricular dilatation
(end diastolic diameter = 45mm) with global hypokinesis
(Figure 1); furthermore an ejection fraction of 20% was
noted (Figure 2).
In addition thoracic radiograph evidenced severe car-
diomegaly. No signiﬁcant ventricular arrhythmias were
detected. Heart failure required medical treatment with
diuretics and digitalis.
Detection of elevated urinary dicarboxylic acids
prompted biochemical studies of fatty acid metabolism,
which disclosed a normal carnitine level (24umol/L).
Moreover the serum acylcarnitine proﬁle showed elevated
levels of C6, C8, C10, and C10.1, that were consistent with
diagnosis of MCADD.
After initial treatment with intravenous glucose, the
patient was fed with a low-fat diet and carnitine supple-
mentation. Over the next six weeks this treatment led to
a dramatic clinical improvement, and she became more
active and gained 400g. Repeated echocardiogram indicated
progressive enhancement of ejection fraction to 35%; in
addition left ventricular end diastolic diameter reduced to
40mm. The patient was discharged home on 90th day.
2. Discussion
Despite advances in drug therapy dilated CMP remains
one of the leading cause of death and heart transplant in
childhood.
Its incidence in infancy is estimated in about 4.4 cases
per 100000 per year, with a high mortality: 50%–60% at two
years.Moreoveraboutonethirdofpatientsdiesorundergoes
heart transplant in the ﬁrst year [1, 2]. Although the most
of cases (66%) are deﬁned “idiopathic”, some CMP may
have an identiﬁable cause [1–4]. Identiﬁcation of underlying
causeofCMPinchildrenmayimproveoutcomeafterspeciﬁc
treatment [1, 3, 4]. Positive family history of heart failure,
sudden death, or genetic syndrome is usually predictive of a
probable cause for CMP [4].
With the exception of medium chain CoA acyl dehy-
drogenase deﬁciency, inborn disorders of fatty-acid β-
oxygenation, have been identiﬁed as possible causes of CMP2 Cardiology Research and Practice
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in infancy [2]. Alteration of mitochondrial beta-oxidation
could be responsible of about 15% of CMP [5]. Congestive
heart failure is determined by reduced energetic production
due to defect of fatty-acids metabolism that reactivates the
less eﬀective foetal glycolytic pathway [6, 7]. Furthermore
accumulation of nonesteriﬁed fatty acids has toxic eﬀects
on ionic channel of cardiac myocytes [5] that may trigger
ventricular arrhythmias even fatal [5, 8, 9].
Fatty-acid β-oxygenation disorders are determined by
an autosomal recessively inherited deﬁciency of a single
enzyme in the mitochondrial metabolism [4, 6]. The β-
oxidation shortens progressively very-long-chain acyl-CoA
through a four-step enzymatic process: carnitine cycle, the
beta-oxidation cycle, the electron transfer pathway, and the
synthesis of ketone bodies. Firstly the carnitine cycle allows
the long chain fatty acids to get into the mitochondria;
otherwise short- and medium-chain fatty acids may enter
directly. Successively the acyl-CoA, produced by the beta-
oxidation cycle, can be utilized in the Kreb’s cycle as well as
in the production of ketone bodies.
The metabolic disorder can involve any of the four
diﬀerent acyl-CoA dehydrogenases, which are of primary
importance for beta-oxidation cycle. Clinical manifestations
of fatty-acid β-oxygenation deﬁciencies are usually pre-
cipitated by fasting, such as infectious disease, and vary
widely according to the speciﬁc enzimatic defect [2, 10–
12]. MCADD is the most common error in mitochondrial
beta-oxidation [13], with a prevalence of 1 case per 15000
in USA [8] and about 4.5 cases/100000 live births in
England [14]. Its clinical consequences are variable; patients
usually manifest before two years of age with life-threatening
hypoketotic hypoglycaemia that can progress to coma and
death [2, 8, 10].
Clinical presentation of MCADD may be dramatic, even
in neonatal age [8, 14], with lethargy, hypoglycaemia, aci-
dosis,andhepatomegaly.Althoughventriculartachyarrhyth-
mias and cardiac arrest may occur, no abnormalities of
myocardial function have been revealed in these patients.
Mortality rate of MCADD ranges from 20% to 25% in
undiagnosed patients [13]. Because prompt diagnosis and
causaltherapymayconsiderablyimproveoutcome,diagnosis
should be considered in neonates and infants with “idio-
pathic” CMP or life-threatening ventricular arrhythmias [5,
8], especially if family history is suggestive of unexplained
sudden infant death. Treatment of fatty-acid oxidation
defects includes avoiding fasting and replacement of dietary
long chain by low dose of medium or short-chain fatty-
acids, providing most of the calories intake as carbohydrates
to reduce lipolysis, whereas L-carnitine supplementation is
controversial [11].
The case described by us is unusual because a compre-
hensive review of literature indicates that MCADD has never
been reported in association with dilated or hypertrophic
CMP.
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